In this issue:
Posttransplant cyclophosphamide is an efficacious prophylactic for GvHD
RIC transplant at first remission prolongs survival in fit older patients with AML
alloHSCT for therapy-related myeloid neoplasm after breast cancer
Frailty associated with increased risk of death after ASCT
Muscle mass loss may be a negative prognostic factor for post-alloHSCT outcome
Improvement in late-mortality after autologous transplant over three decades
Long-term patient-reported neurocognitive outcomes in adult survivors of HSCT
Baseline genetics determine outcomes after transplant in older patients with AML
Please login below to download this issue (PDF)